565 related articles for article (PubMed ID: 25721380)
1. Cost-effectiveness of routine varicella vaccination using the measles, mumps, rubella and varicella vaccine in France: an economic analysis based on a dynamic transmission model for varicella and herpes zoster.
Littlewood KJ; Ouwens MJ; Sauboin C; Tehard B; Alain S; Denis F
Clin Ther; 2015 Apr; 37(4):830-841.e7. PubMed ID: 25721380
[TBL] [Abstract][Full Text] [Related]
2. The impact of 2-dose routine measles, mumps, rubella, and varicella vaccination in France on the epidemiology of varicella and zoster using a dynamic model with an empirical contact matrix.
Ouwens MJ; Littlewood KJ; Sauboin C; Téhard B; Denis F; Boëlle PY; Alain S
Clin Ther; 2015 Apr; 37(4):816-829.e10. PubMed ID: 25726457
[TBL] [Abstract][Full Text] [Related]
3. Assessing the introduction of universal varicella vaccination in the Netherlands.
Boot HJ; de Melker HE; Stolk EA; de Wit GA; Kimman TG
Vaccine; 2006 Sep; 24(37-39):6288-99. PubMed ID: 16790302
[TBL] [Abstract][Full Text] [Related]
4. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
Marin M; Broder KR; Temte JL; Snider DE; Seward JF;
MMWR Recomm Rep; 2010 May; 59(RR-3):1-12. PubMed ID: 20448530
[TBL] [Abstract][Full Text] [Related]
5. Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.
Knuf M; Zepp F; Helm K; Maurer H; Prieler A; Kieninger-Baum D; Douha M; Willems P
Eur J Pediatr; 2012 Mar; 171(3):463-70. PubMed ID: 21935584
[TBL] [Abstract][Full Text] [Related]
6. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial.
Prymula R; Bergsaker MR; Esposito S; Gothefors L; Man S; Snegova N; Štefkovičova M; Usonis V; Wysocki J; Douha M; Vassilev V; Nicholson O; Innis BL; Willems P
Lancet; 2014 Apr; 383(9925):1313-1324. PubMed ID: 24485548
[TBL] [Abstract][Full Text] [Related]
7. Vaccines for measles, mumps, rubella, and varicella in children.
Di Pietrantonj C; Rivetti A; Marchione P; Debalini MG; Demicheli V
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD004407. PubMed ID: 32309885
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubella-varicella vaccine in healthy Indian children from 9 months of age: a phase III, randomised, non-inferiority trial.
Lalwani S; Chatterjee S; Balasubramanian S; Bavdekar A; Mehta S; Datta S; Povey M; Henry O
BMJ Open; 2015 Sep; 5(9):e007202. PubMed ID: 26362659
[TBL] [Abstract][Full Text] [Related]
9. Epidemiological Impact and Cost-Effectiveness of Varicella Vaccination Strategies in the United Kingdom.
Akpo EIH; Cristeau O; Hunjan M; Casabona G
Clin Infect Dis; 2021 Dec; 73(11):e3617-e3626. PubMed ID: 33173938
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of varicella and herpes zoster vaccination in Sweden: An economic evaluation using a dynamic transmission model.
Wolff E; Widgren K; Scalia Tomba G; Roth A; Lep T; Andersson S
PLoS One; 2021; 16(5):e0251644. PubMed ID: 33984060
[TBL] [Abstract][Full Text] [Related]
11. Early impact of universal varicella vaccination on childhood varicella and herpes zoster hospitalizations in Brazil.
Scotta MC; Paternina-de la Ossa R; Lumertz MS; Jones MH; Mattiello R; Pinto LA
Vaccine; 2018 Jan; 36(2):280-284. PubMed ID: 29198917
[TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom.
van Hoek AJ; Melegaro A; Gay N; Bilcke J; Edmunds WJ
Vaccine; 2012 Feb; 30(6):1225-34. PubMed ID: 22119592
[TBL] [Abstract][Full Text] [Related]
13. [Chickenpox: sufficient reasons for the introduction of vaccination].
Rümke H; de Groot R
Ned Tijdschr Geneeskd; 2006 Dec; 150(48):2630-2. PubMed ID: 17205937
[TBL] [Abstract][Full Text] [Related]
14. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Combination Measles-Mumps-Rubella-Varicella Vaccine Introduction in Australia.
Macartney K; Gidding HF; Trinh L; Wang H; Dey A; Hull B; Orr K; McRae J; Richmond P; Gold M; Crawford N; Kynaston JA; McIntyre P; Wood N;
JAMA Pediatr; 2017 Oct; 171(10):992-998. PubMed ID: 28806450
[TBL] [Abstract][Full Text] [Related]
16. Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries.
Damm O; Ultsch B; Horn J; Mikolajczyk RT; Greiner W; Wichmann O
BMC Public Health; 2015 Jun; 15():533. PubMed ID: 26041469
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and reactogenicity of tetravalent vaccine for measles, mumps, rubella and varicella (MMRV) in healthy children: a meta-analysis of randomized controlled trials.
Leung JH; Hirai HW; Tsoi KK
Expert Rev Vaccines; 2015; 14(8):1149-57. PubMed ID: 26081133
[TBL] [Abstract][Full Text] [Related]
18. [Modelling the impact of vaccination on the epidemiology of varicella zoster virus].
Bonmarin I; Santa-Olalla P; Lévy-Bruhl D
Rev Epidemiol Sante Publique; 2008 Oct; 56(5):323-31. PubMed ID: 18951741
[TBL] [Abstract][Full Text] [Related]
19. The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France.
Coudeville L; Paree F; Lebrun T; Sailly J
Vaccine; 1999 Jan; 17(2):142-51. PubMed ID: 9987148
[TBL] [Abstract][Full Text] [Related]
20. One or two doses of live varicella virus-containing vaccines: Efficacy, persistence of immune responses, and safety six years after administration in healthy children during their second year of life.
Henry O; Brzostek J; Czajka H; Leviniene G; Reshetko O; Gasparini R; Pazdiora P; Plesca D; Desole MG; Kevalas R; Gabutti G; Povey M; Innis B
Vaccine; 2018 Jan; 36(3):381-387. PubMed ID: 29224964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
